(Page 2 of 2)
partnership. They include a candidate aimed at treating thrombosis and angioedema, and another for renal cell carcinoma. However, like the two partnered programs, they are all still in the pre-clinical stage. It’s doubtful that the company will get be able to advance any of these compounds into clinical trials in 2017, the RBC Capital Markets analysts wrote in their research note.